Latest news

New CRISPR/Cas9 license agreement for ERS Genomics and Cytosurge

  Dublin, Ireland, June 28, 2022: ERS Genomics Limited (‘ERS’) is pleased to announce a new license agreement with Cytosurge AG (“Cytosurge”). This is a non-exclusive licensing agreement granting Cytosurge access to the ERS CRISPR/Cas9 patent portfolio. ERS, co-founded by Dr. Emmanuelle Charpentier, 2020 Nobel Prize winner for gene-editing, provides access to the foundational CRISPR/Cas9 intellectual property. Eighty-nine patents are currently held in over 90 countries. ERS CEO, Eric Rhodes commented: “CRISPR/Cas9 is a powerful genome engineering tool that has revolutionized biotechnology. We are pleased to support Cytosurge, an exciting and progressive leader in precision single-cell manipulation, in their ongoing

Read more <i class="fal fa-long-arrow-right"></i>

Top news